They're like a **Moderna** for antibiotic-resistant infections, developing treatments using specialized viruses (bacteriophages) instead of mRNA.

Think of them as a **CRISPR Therapeutics** for bacteria, using viruses to precisely target and kill superbug infections.

• AP-SA02: A bacteriophage therapeutic candidate for the treatment of Staphylococcus aureus bacteremia.
• AP-PA02: A bacteriophage therapeutic candidate for the treatment of Pseudomonas aeruginosa infections.
• AP-PA03: A bacteriophage therapeutic candidate for the treatment of pneumonia.
• Development Collaboration with Merck & Co.: A partnership focused on developing synthetic bacteriophage candidates to target various undisclosed infectious disease agents.

Armata Pharmaceuticals (ARMP) is a clinical-stage biotechnology company. As such, it does not currently have commercial products approved for sale to individuals or healthcare providers. Its primary revenue generation at this stage comes from collaboration agreements with other companies.

Based on the provided information, Armata Pharmaceuticals has a partnership agreement with:

• Merck & Co. (MRK)

Merck & Co. can be considered a major customer or partner, providing funding and collaboration for the development of synthetic bacteriophage candidates.

Deborah Birx, M.D. Chief Executive Officer

Dr. Deborah Birx was appointed Chief Executive Officer of Armata on July 10, 2023. She is a renowned medical expert and leader, having most recently served as the response coordinator of the White House Coronavirus Task Force. Her extensive career includes roles as Ambassador-at-Large, Coordinator of United States Government Activities to Combat HIV/AIDS, and U.S. Special Representative for Global Health Diplomacy. Dr. Birx also directed the U.S. Global AIDS Coordinator, overseeing the President's Emergency Plan for AIDS Relief (PEPFAR) at the CDC, and was the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research. She served in the United States Army from 1980 until 2008, retiring with the rank of colonel. Prior to joining Armata, she was a member of Innoviva's Board of Directors from March 2021 until July 2023.

David House Senior Vice President, Finance and Principal Financial Officer

Mr. David House was appointed Senior Vice President, Finance and Principal Financial Officer on August 16, 2024. Previously, he served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc. from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company's acquisition by Blackstone. His experience also includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc., a contract development and manufacturing organization.

Pierre Kyme, Ph.D. Chief Business Officer

Dr. Pierre Kyme was appointed Chief Business Officer of Armata in June 2024. He is dedicated to Armata's business and corporate development activities, a role he began at C3J Therapeutics in 2015, which later merged to form Armata Pharmaceuticals. Dr. Kyme also serves on the boards of directors of Armata's Australian subsidiaries.

Bani Tchekanova, Ph.D. Head of Regulatory Strategy and Operations

Dr. Bani Tchekanova was appointed Head of Regulatory Strategy and Operations in July 2025. She brings over 25 years of diverse experience in global drug development and regulatory affairs, covering a wide range of therapeutic areas, including infectious disease, oncology, dermatology, ophthalmology, cardiovascular, neuroscience, and gene therapy. Before joining Armata, Dr. Tchekanova served as a Chief Principal Advisor at ClinReg Partners, LLC.

Key Risks to Armata Pharmaceuticals (ARMP)

Armata Pharmaceuticals, Inc. (ARMP), as a clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant infections, faces several significant risks inherent to its stage of development and the novel nature of its technology.

1. Clinical Trial and Regulatory Approval Risk: The most immediate and significant risk for Armata Pharmaceuticals is the successful completion of its clinical trials and subsequent regulatory approval of its product candidates, such as AP-SA02, AP-PA02, and AP-PA03. As a company with no reported revenue, its entire business model hinges on these candidates proving safe and effective in human trials and gaining approval from regulatory bodies. Setbacks in late-stage trials or delays in regulatory processes could severely impact the company's prospects and valuation.
2. Financing and Liquidity Risk: Armata Pharmaceuticals currently operates without revenue, relying on funding to advance its research and development pipeline. The company faces ongoing losses, limited cash, and significant liabilities, indicating potential liquidity challenges. The need to raise additional capital to fund extensive R&D and clinical trials poses a substantial risk, with the potential for shareholder dilution or challenges in securing necessary financing.
3. Commercial Viability and Market Acceptance of Bacteriophage Therapeutics: Even with successful clinical trials, Armata Pharmaceuticals faces risks related to the commercial viability and market acceptance of bacteriophage therapy. As an emerging therapeutic approach, there is limited broad awareness and acceptance among medical practitioners and the public. Challenges include competition from existing and new antibiotic treatments, potential for bacterial resistance to phages, and regulatory hurdles in rapidly adapting phage formulations to address evolving resistance.

Armata Pharmaceuticals (ARMP) focuses on developing bacteriophage therapeutics for antibiotic-resistant infections. The addressable markets for its main product candidates are as follows:

• AP-SA02 for Staphylococcus aureus bacteremia: The Staphylococcus aureus Bacteremia market size in the 7MM (United States, EU5, and Japan) is anticipated to grow with a significant Compound Annual Growth Rate (CAGR) during the period of 2020-2034. The global methicillin-resistant Staphylococcus aureus (MRSA) drugs market, a relevant subset, was valued at USD 2.15 billion in 2023 and is projected to grow at a CAGR of 5.51% from 2024 to 2030.
• AP-PA02 for Pseudomonas aeruginosa: The global Pseudomonas aeruginosa infection treatment market was estimated at USD 2.3 billion in 2026 and is projected to reach USD 3.02 billion by 2031, growing at a CAGR of 5.58%. Other estimates for the global market include USD 5.62 billion in 2024, poised to grow to USD 11.33 billion by 2033 with an 8.1% CAGR.
• AP-PA03 for pneumonia: The global pneumonia therapeutics market was valued at USD 2.28 billion in 2023 and is projected to grow at a CAGR of 9.4% from 2024 to 2030. Another assessment places the global pneumonia therapeutics market size at USD 3.3 billion in 2024, with expectations to reach USD 7.4 billion by 2034, exhibiting a CAGR of 8.5% during the forecast period.

Here are 3-5 expected drivers of future revenue growth for Armata Pharmaceuticals (ARMP) over the next 2-3 years:

1. Successful Advancement and Commercialization Opportunities for AP-SA02: Armata Pharmaceuticals anticipates initiating a Phase 3 superiority trial for its lead therapeutic candidate, AP-SA02, in the second half of 2026, targeting complicated Staphylococcus aureus bacteremia (SAB). The U.S. FDA has confirmed that the safety and efficacy data from the Phase 2a diSArm study support this advancement. Additionally, AP-SA02 received Qualified Infectious Disease Product (QIDP) designation in February 2026, which can provide incentives such as a five-year extension of market exclusivity upon approval. Positive progress through pivotal late-stage trials could lead to significant future milestone payments from partnerships or eventual commercialization, driving substantial revenue growth.
2. Progress in Clinical Development and Partnering for AP-PA02: The company has completed both the Phase 1b/2a SWARM-P.a. study for AP-PA02 in cystic fibrosis (CF) and the Phase 2 Tailwind study for AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB). Encouraging topline results from the Tailwind study, announced in December 2024, demonstrated the potential of AP-PA02 as a monotherapy treatment. Continued positive clinical data for AP-PA02 could attract new development partners or lead to out-licensing agreements, generating revenue through milestone payments and future royalties.
3. Advancement of AP-PA03 for Pneumonia: Armata is advancing a distinct phage cocktail, AP-PA03, for the treatment of pneumonia, with the candidate entering manufacturing. Progression of this program through manufacturing and into clinical development stages would increase its value and potential for future partnerships or commercialization, thereby contributing to revenue growth.
4. Milestone Payments from the Merck & Co. Partnership: Armata Pharmaceuticals maintains a partnership agreement with Merck & Co. for the development of proprietary synthetic bacteriophage candidates targeting undisclosed infectious disease agents. Successful progression of these candidates through developmental stages could trigger milestone payments from Merck, contributing to Armata's revenue.
5. Continued Acquisition of Grant and Award Revenue: The company has historically received, and continues to receive, grant and award revenue, such as from the Medical Technology Enterprise Consortium (MTEC) for its AP-SA02 program. For instance, it recognized $1.2 million in grant and award revenue for the three months ended September 30, 2025. Ongoing and new non-dilutive grants from governmental or non-profit organizations will provide funding for their research and development efforts, contributing to the company's revenue stream.

Share Issuance

• On February 9, 2022, Armata Pharmaceuticals entered into a securities purchase agreement to sell common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc., for gross proceeds of $45 million. This transaction involved the sale of 9.0 million newly issued shares of Armata's common stock.
• As of December 1, 2025, Armata Pharmaceuticals established an at-the-market (ATM) equity offering program, allowing the company to offer and sell up to $100 million of its common stock.
• As of Q3 2025, Armata Pharmaceuticals had 36 million shares outstanding.

Inbound Investments

• Innoviva Strategic Opportunities LLC, a subsidiary of Innoviva, Inc. and Armata's largest shareholder, made a $45 million investment in Armata Pharmaceuticals in February 2022 through a securities purchase agreement.
• In August 2025, Armata Pharmaceuticals secured a $15 million loan from Innoviva Strategic Opportunities LLC through a secured credit agreement, maturing in January 2029, to advance its lead therapeutic phage candidate, AP-SA02.
• Armata Pharmaceuticals received an additional $4.65 million in non-dilutive funding from a U.S. Department of Defense (DoD) award in May 2025.

Capital Expenditures

• Armata Pharmaceuticals invested $242,000 in capital expenditures in Q3 2025, primarily to fund long-term assets and infrastructure.
• In November 2025, the company announced the formal commissioning of a state-of-the-art cGMP (current Good Manufacturing Practice) phage manufacturing facility in Los Angeles, California, indicating significant investment in its infrastructure for product development.
• The company's research and development facility in Los Angeles is equipped with two licensed cGMP drug manufacturing suites for the production, testing, and release of clinical trial material, representing ongoing capital investment in its operational capabilities.